Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 187

Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM). 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glioblastoma Multiforme (GBM).
- A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Glioblastoma Multiforme (GBM) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Glioblastoma Multiforme (GBM) Therapeutic Products under Development, Key Players in Glioblastoma Multiforme (GBM) Therapeutics, Glioblastoma Multiforme (GBM) Pipeline Overview, Glioblastoma Multiforme (GBM) Pipeline, Glioblastoma Multiforme (GBM) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glioblastoma Multiforme (GBM) Overview
Therapeutics Development
An Overview of Pipeline Products for Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies
Glioblastoma Multiforme (GBM) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Glioblastoma Multiforme (GBM) Therapeutics – Products under Development by Companies
Glioblastoma Multiforme (GBM) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Glioblastoma Multiforme (GBM) Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Lentigen Corporation
Sangamo BioSciences, Inc.
YM BioSciences Inc.
Ark Therapeutics Group plc
Millennium Pharmaceuticals, Inc.
Novartis AG
ImClone Systems Incorporated
Actelion Ltd
Eisai Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Cell Therapeutics, Inc.
Exelixis, Inc.
Aduro BioTech
Geron Corporation
Merck KGaA
Access Pharmaceuticals, Inc.
EntreMed, Inc.
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
Lixte Biotechnology Holdings, Inc.
Northwest Biotherapeutics, Inc.
Circadian Technologies Limited
Oncolytics Biotech Inc.
Oncothyreon Inc
Peregrine Pharmaceuticals, Inc.
Pharmacyclics, Inc.
PhytoMedical Technologies, Inc.
Transgene SA
Threshold Pharmaceuticals, Inc.
Bradmer Pharmaceuticals Inc.
Proximagen Neuroscience plc.
Protox Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Ambit Biosciences Corporation
Immupharma Plc
immatics biotechnologies GmbH
Apogenix GmbH
Indena S.p.A.
Oncolin Therapeutics, Inc.
Diffusion Pharmaceuticals LLC
Arno Therapeutics, Inc.
Reata Pharmaceuticals, Inc.
Vascular Biogenics Ltd.
BioCancell Therapeutics, Inc.
Axelar AB
Advenchen Laboratories, LLC
Myriad Pharmaceuticals, Inc.
NOXXON Pharma AG
BiPar Sciences, Inc.
ChemoCentryx, Inc.
TVAX Biomedical, LLC
Sirnaomics, Inc.
AVEO Pharmaceuticals, Inc.
Nexgenix Pharmaceuticals, LLC
Archer Biosciences, Inc
Direct Therapeutics, Inc.
R&D Systems, Inc.
TAU Therapeutics, LLC
CytomX, LLC.
Glioblastoma Multiforme (GBM) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Enzastaurin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rindopepimut - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IL13-PE38QQR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cerepro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recentin + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide + Temozolomide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temodal + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glioblastoma Multiforme (GBM) Therapeutics – Drug Profile Updates
Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products
Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products
Glioblastoma Multiforme (GBM) – Product Development Milestones
Featured News & Press Releases
Jan 11, 2012: Antisense Pharma To Pursue First-Line Treatment With Trabedersen, Terminates 2nd Line Phase III High Grade Glioma Trial
Jan 09, 2012: NW Bio Reaches 25 Clinical Trial Sites In Ongoing Clinical Trial Of DCVax
Jan 08, 2012: Circadian Commences First Phase I Clinical Trial Of VGX-100 In Cancer Patients
Dec 02, 2011: MDxHealth Enters Agreement With Celldex For Use Of MGMT Epigenetic Test In Phase III Rindopepimut Study In Brain Cancer
Dec 01, 2011: Celldex Initiates Pivotal International Phase III Trial Of Rindopepimut In Patients With Glioblastoma
Nov 21, 2011: Celldex Reports Positive Mature Survival Data From Rindopepimut Phase II Brain Cancer Study At SNO 2011
Nov 18, 2011: ImmunoCellular Therapeutics To Present Data On ICT-107 At 16th Annual Meeting Of Society For Neuro-Oncology
Nov 14, 2011: Lentigen And UH Case Medical Center Initiate Phase I Trial Using Gene Therapy And Bone Marrow Stem Cells In Treatment Of Brain Cancer
Oct 31, 2011: Celldex Therapeutics Receives Orphan Drug Designation In EU For Rindopepimut For Glioblastoma
Oct 31, 2011: Circadian Receives FDA IND Approval To Begin Clinical Trials With VGX-100 For Treatment Of Solid Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Glioblastoma Multiforme (GBM), H1 2012
Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Bristol-Myers Squibb Company, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
Lentigen Corporation, H1 2012
Sangamo BioSciences, Inc., H1 2012
YM BioSciences Inc., H1 2012
Ark Therapeutics Group plc, H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
ImClone Systems Incorporated, H1 2012
Actelion Ltd, H1 2012
Eisai Co., Ltd., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Cell Therapeutics, Inc., H1 2012
Exelixis, Inc., H1 2012
Aduro BioTech, H1 2012
Geron Corporation, H1 2012
Merck KGaA, H1 2012
Access Pharmaceuticals, Inc., H1 2012
EntreMed, Inc., H1 2012
Celldex Therapeutics, Inc., H1 2012
ImmunoCellular Therapeutics, Ltd., H1 2012
Lixte Biotechnology Holdings, Inc., H1 2012
Northwest Biotherapeutics, Inc., H1 2012
Circadian Technologies Limited, H1 2012
Oncolytics Biotech Inc., H1 2012
Oncothyreon Inc, H1 2012
Peregrine Pharmaceuticals, Inc., H1 2012
Pharmacyclics, Inc., H1 2012
PhytoMedical Technologies, Inc., H1 2012
Transgene SA, H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
Bradmer Pharmaceuticals Inc., H1 2012
Proximagen Neuroscience plc., H1 2012
Protox Therapeutics Inc., H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
INSYS Therapeutics, Inc., H1 2012
Ambit Biosciences Corporation, H1 2012
Immupharma Plc, H1 2012
immatics biotechnologies GmbH, H1 2012
Apogenix GmbH, H1 2012
Indena S.p.A., H1 2012
Oncolin Therapeutics, Inc., H1 2012
Diffusion Pharmaceuticals LLC, H1 2012
Arno Therapeutics, Inc., H1 2012
Reata Pharmaceuticals, Inc., H1 2012
Vascular Biogenics Ltd., H1 2012
BioCancell Therapeutics, Inc., H1 2012
Axelar AB, H1 2012
Advenchen Laboratories, LLC, H1 2012
Myriad Pharmaceuticals, Inc., H1 2012
NOXXON Pharma AG, H1 2012
BiPar Sciences, Inc., H1 2012
ChemoCentryx, Inc., H1 2012
TVAX Biomedical, LLC, H1 2012
Sirnaomics, Inc., H1 2012
AVEO Pharmaceuticals, Inc., H1 2012
Nexgenix Pharmaceuticals, LLC, H1 2012
Archer Biosciences, Inc, H1 2012
Direct Therapeutics, Inc., H1 2012
R&D Systems, Inc., H1 2012
TAU Therapeutics, LLC, H1 2012
CytomX, LLC., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Glioblastoma Multiforme (GBM) Therapeutics – Drug Profile Updates
Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products
Glioblastoma Multiforme (GBM) Therapeutics – Discontinued Products (Contd..1)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..1)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..2)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..3)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..4)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..5)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..6)
Glioblastoma Multiforme (GBM) Therapeutics – Dormant Products (Contd..7)

List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2012
Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Rheumatoid Arthritis - Pipeline Review, H1 2013
• Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Hepatitis - Pipeline Review, H1 2013
• Neuropathic Pain - Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Inflammatory Bowel Disease - Pipeline Review, H1 2013
• Age Related Macular Degeneration - Pipeline Review, H1 2013
• Diabetes - Pipeline Review, H1 2012